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Abstract
Identification of etiology remains a significant challenge in the diagnosis of infectious diseases, particularly in resource-poor
settings. Viral, bacterial, and fungal pathogens, as well as parasites, play a role for many syndromes, and optimizing a single
diagnostic system to detect a range of pathogens is challenging. The TaqMan Array Card (TAC) is a multiple-pathogen
detection method that has previously been identified as a valuable technique for determining etiology of infections and
holds promise for expanded use in clinical microbiology laboratories and surveillance studies. We selected TAC for use in the
Aetiology of Neonatal Infection in South Asia (ANISA) study for identifying etiologies of severe disease in neonates in
Bangladesh, India, and Pakistan. Here we report optimization of TAC to improve pathogen detection and overcome
technical challenges associated with use of this technology in a large-scale surveillance study. Specifically, we increased the
number of assay replicates, implemented a more robust RT-qPCR enzyme formulation, and adopted a more efficient
method for extraction of total nucleic acid from blood specimens. We also report the development and analytical validation
of ten new assays for use in the ANISA study. Based on these data, we revised the study-specific TACs for detection of 22
pathogens in NP/OP swabs and 12 pathogens in blood specimens as well as two control reactions (internal positive control
and human nucleic acid control) for each specimen type. The cumulative improvements realized through these
optimization studies will benefit ANISA and perhaps other studies utilizing multiple-pathogen detection approaches. These
lessons may also contribute to the expansion of TAC technology to the clinical setting.
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Introduction
Identifying infectious etiologies is extremely complex for many
clinical syndromes. The diversity and fastidious nature of
pathogens causing infection and the lack of available diagnostic
tests of sufficient quality and breadth contribute to the low
proportion of cases with clearly identified etiology. The infectious
etiology of community-acquired respiratory infections may remain
unidentified in a large proportion of cases, even when advanced
diagnostic technologies are employed [1–5]. In resource-poor
settings, this proportion may be even higher as a result of factors
which impede utilization of sophisticated testing procedures,
including logistical challenges to specimen collection and handling,
as well as the lack of adequate laboratory space or highly trained
personnel. Obtaining an appropriate high-quality specimen at the
proper time can be especially challenging within certain popula-
tions due to limited care-seeking or inadequate access to quality
materials. High potential for contamination in non-sterile collec-
tion settings is another considerable challenge to obtaining quality
results in resource-poor areas. Interpretation of results from
respiratory specimens is an additional challenge since simply
confirming the presence of a microorganism does not indicate
whether it is etiologic. Many potential pathogens are carried
asymptomatically in a proportion of individuals within a popula-
tion. Furthermore, when more than one potential pathogen is
identified, determining which organism(s) contributes to disease
can be difficult.
Nucleic acid detection methods have increasingly been replac-
ing or augmenting traditional laboratory techniques for identifi-
cation of etiology of infectious disease syndromes. Multiple
pathogen detection approaches which incorporate these highly
sensitive methods into high-throughput strategies are being
implemented as tools for identification of etiology in clinical
syndromes where many infectious agents may contribute to disease
[6]. The increased availability of these multi-pathogen molecular
detection methods enables a more comprehensive evaluation of
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patient specimens in a relatively short period of time, resulting in
an improved clinical picture for consideration by the physician.
One technology which has emerged as a useful method for
multiple pathogen detection is the TaqMan Array Card (TAC),
formerly known as the TaqMan Low Density Array (TLDA) card
(Life Technologies, Foster City, CA, USA). This 384-well
microfluidic array consists of dried-down individual singleplex
qPCR reactions for simultaneous detection of up to 48 targets
from a single specimen. Each TAC contains eight individual
microfluidic channels that can be loaded with PCR reactions
containing nucleic acid extract from a clinical specimen or control
material. TAC technology has previously been evaluated for
detection of respiratory pathogens [7], enteropathogens [8], and
biothreat agents [9,10], and has been routinely employed to
determine etiology of respiratory disease outbreaks in the United
States [11].
Recently, this approach has been proposed as an effective
strategy for identifying disease etiologies in large-scale surveillance
studies [8,12]. TAC was selected for use in the Aetiology of
Neonatal Infection in South Asia (ANISA) study, supported by the
Bill and Melinda Gates Foundation (BMGF). This study aims to
address the critical deficiency in childhood survival in South Asia,
a region of the world where pneumonia, sepsis, and diarrheal
disease cause the majority of childhood deaths, over 40% of which
occur in neonates [13]. The current rate of decline in mortality in
this region is not sufficient to meet the target of the United Nations
Millennium Development Goal 4 (MDG 4) of a two-thirds
reduction in child mortality by 2015 [14]. The goals of the ANISA
study are to determine the population-based incidence, etiology,
and characteristics of community-acquired infections and identify
associated risk factors in neonates in Bangladesh, India, and
Pakistan. As part of this study, respiratory and blood specimens
will be tested using both traditional and advanced diagnostic
techniques in order to identify the leading causes of neonatal
infections in these countries. TAC was selected for use in this
project based upon (i) prior application of this technology for
pathogen detection, (ii) ability to customize a panel of pathogen
targets, (iii) requirement for minimal volume of specimen, (iv)
reduced potential for contamination due to the closed system
format of TAC, and (v) ease of use, including minimal ‘‘hands-on’’
setup.
Despite its favorable advantages, a number of technical
challenges existed for application of TAC to the ANISA study.
First, the utility of TAC for pathogen detection in human blood
specimens has not previously been investigated. A recent study
demonstrated low sensitivity of TAC for detection of several
bacterial agents in blood from murine infection models [10].
Molecular detection of pathogens in blood suffers from poor
sensitivity, and blood volumes collected from neonates are limited.
Therefore, inclusion of this specimen type in the ANISA study
required modification and optimization of the nucleic acid
extraction protocol as well as other experimental parameters in
order to improve the sensitivity of this technology for pathogen
detection in blood. Secondly, the diversity of pathogens, including
viruses, bacteria, and parasites, created an additional challenge
since many of these pathogen-specific assays had not been
designed and/or evaluated for performance on the TAC. The
diverse repertoire of pathogens included both DNA and RNA
genomes, requiring a reverse transcription step for all assays due to
the integrated format of TAC. Therefore, assays designed to detect
DNA targets also required optimization with RT-qPCR cycling
conditions and enzyme formulations.
Here we report data from a series of experiments designed to
optimize the TAC methodology for use in the ANISA study.
Improvements include enhancement of nucleic acid extraction
from blood using an initial lysis step, implementation of an
improved RT-qPCR enzyme system, and optimization of card
design and production. The results from these optimization studies
are being applied to TAC testing procedures in the ANISA study
in order to achieve the highest sensitivity and specificity possible
for determining infectious etiologies among enrolled neonates. In
some cases, the findings reported here may also be applicable to
studies using other specimen types along with testing modalities
that may hold utility within the clinical setting.
Materials and Methods
Ethics Statement
The study protocols were approved by the International Centre
for Diarrhoeal Disease Research, Bangladesh (IDCCR,B, Dhaka,
Bangladesh) and Aga Khan University (Karachi, Pakistan).
Written informed consent was obtained from a parent or guardian
prior to specimen collection from neonate.
Real-time PCR Assay Design and Analytical Validation
A panel of neonatologists with expertise in neonatal infection
and South Asia was convened, and the Delphi method [15] was
used to identify organisms of the highest priority for testing in
nasopharyngeal (NP) and oropharyngeal (OP) swabs and blood
specimens from neonates enrolled in the ANISA study. Primers
and hydrolysis probes were designed for specific detection of
organisms for which existing assays were not currently available in
our laboratories, including Toxoplasma gondii, Staphylococcus aureus,
Klebsiella pneumoniae, Escherichia coli/Shigella spp., Pseudomonas aerugi-
nosa, Ureaplasma spp., Chlamydia trachomatis, Acinetobacter baumannii,
Streptococcus agalactiae (Group B Streptococcus), and Neisseria meningitidis
(Table S1 in File S1). In most cases, oligonucleotides were
designed using Primer Express 3.0 software (Applied Biosystems,
Foster City, CA) with slight modifications to optimize melting
temperatures (Tm) and minimize intra- and inter-molecular
interactions. Specificity of each set of oligonucleotides for the
intended genus and/or species was assessed by sequence
comparison using Basic Local Alignment Search Tool (BLAST)
within the National Center for Biotechnology Information (NCBI)
database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Primers and
hydrolysis probe previously reported for detection of Salmonella
spp. were validated using the experimental conditions for this
study (Table S1 in File S1) [16]. Performance evaluation of other
assays included on the ANISA study TAC designs (Figure 1) was
reported previously [7]. Primers and hydrolysis probes used for
analytical validation were manufactured by the Biotechnology
Core Facility at the Centers for Disease Control and Prevention
(CDC, Atlanta, GA, USA).
All newly developed real-time PCR assays were evaluated using
individual RT-qPCR reactions prior to use on the TAC format.
Each assay was tested using nuclease-free water as template (n
$95) to ensure no fluorescence amplification signal was observed
in the absence of nucleic acid. The limit of detection was
independently determined for each assay by testing at least 3
replicates each of a 10-fold dilution series of specific total nucleic
acid ranging from 0.1 fg/mL to 1 ng/mL. Inclusivity was assessed
by testing representative isolates, including various subspecies,
serotypes, or clonal groups, as appropriate (Table S2 in File S1).
Specificity of each assay was assessed by testing 15 ng of nucleic
acid from at least 200 different bacteria, viruses, and protozoa
representing 36 genera and 143 species. In addition to the most
closely related species to each target pathogen, this panel also
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included commensals of the respiratory tract and human nucleic
acid.
Oligonucleotide Preparation for TAC Manufacturing
Oligonucleotides for TAC production were manufactured by
Integrated DNA Technologies (Coralville, IA, USA) or Biosearch
Technologies (Novato, CA, USA), diluted and combined to 206
reaction concentration, and provided to Life Technologies (Foster
City, CA, USA) for custom manufacturing of study-specific TACs
(Figure 1). The 206 concentration corresponds to a 16 final
reaction concentration in the 1 mL reaction within each TAC well
on the finished array card. For optimization of primer and probe
concentration, oligonucleotides were also prepared at 406
concentration for TAC production, resulting in 26 final reaction
concentration in each well. The Optimization TAC configuration
(Figure 1) was designed to assess the impact of oligonucleotide
concentration on pathogen detection and consisted of five
replicates of four targets (M. pneumoniae, S. pneumoniae, Group B
Streptococcus, and human parainfluenza virus 2), each spotted in two
final reaction concentrations, 16and 26 (Figure 1). Total nucleic
acid was extracted from a series of 10-fold dilutions of each
organism and tested to determine the potential impact of
oligonucleotide concentration on assay sensitivity.
Clinical Specimens
Clinical specimens, including whole blood and combined NP/
OP swabs, were obtained from enrolled neonates at three ANISA
study sites: Sylhet, Bangladesh; Karachi, Pakistan; and Matiari,
Pakistan. NP/OP swabs were collected and placed together in
1 mL Universal Transport Media (UTM, Copan Diagnostics,
Murrieta, CA, USA) and stored at 270uC prior to extraction.
Blood specimens were collected in standard EDTA collection
tubes and stored at 4uC for short-term storage (#72 h post-
collection) or 270uC for longer storage prior to nucleic acid
extraction and testing by TAC.
Figure 1. ANISA-specific TAC configurations. Original ANISA NP/OP TAC, Original ANISA Blood TAC, Optimization TAC, Revised ANISA NP/OP
TAC, Revised ANISA Blood TAC. Target designations include: MYPN, Mycoplasma pneumoniae; CHTR, Chlamydia trachomatis; CHPN, Chlamydophila
pneumoniae; URUP, Ureaplasma spp.; BOP1, Bordetella pertussis; ADEV, Adenovirus; FLUA, Influenza A; FLUB, Influenza B; PIV1, Parainfluenza virus 1;
PIV2, Parainfluenza virus 2; PIV3, Parainfluenza virus 3; RESV, Respiratory Syncytial Virus; HPEV, Human Parechovirus; IPCO, Internal Positive Control;
GADH, Glyceraldehyde phosphate dehydrogenase (Manufacturing control); ENTV, Enterovirus; HMPV, Human Metapneumovirus; RUBV, Rubella virus;
STPN, Streptococcus pneumoniae; KLPN, Klebsiella pneumoniae; ECSH, Escherichia coli/Shigella spp.; RHIV, Rhinovirus; GBST, Group B Streptococcus;
HSV1, Herpes Simplex Virus 1; HSV2, Herpes Simplex Virus 2; RNP3, Human RNaseP; STAU, Staphylococcus aureus; GAST, Group A Streptococcus; PSAE,
Pseudomonas aeruginosa; HIAT, Haemophilus influenzae; HITB, Haemophilus influenzae type B; SALS, Salmonella spp.; ABAU, Acinetobacter baumannii;
CYMV, Cytomegalovirus; TOXG, Toxoplasma gondii; NMEN, Neisseria meningitidis. All oligonucleotides were spotted at 16 final concentration except
where noted by * where concentration is 26. #Duplex assay consisting of RNP3 assay with FAM-labeled probe and IPCO assay with VIC-labeled
probe.
doi:10.1371/journal.pone.0066183.g001
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Specimen Processing and Nucleic Acid Extraction
Total nucleic acid (TNA) was extracted from clinical specimens
using the MagNA Pure Compact instrument (Roche Applied
Sciences, Indianapolis, IN, USA) with Nucleic Acid Isolation Kit I
and Total NA Plasma protocol. For NP/OP swab specimens,
400 mL of UTM was extracted and eluted in 100 mL. For
extraction of whole blood, 300 mL of blood in EDTA was mixed
with 100 mL of a freshly-prepared solution of lytic enzymes
consisting of 1.5 mg/mL lysostaphin, 2500 U/mL mutanolysin,
and 200 mg/mL lysozyme (Sigma-Aldrich, St. Louis, MO, USA)
in Tris-EDTA (TE) buffer and incubated at 37uC for 60 min.
prior to extraction on the MagNA Pure Compact, with elution in
100 mL. To assess the potential impact of an initial lysis step on
recovery of TNA from a variety of pathogens, healthy donor blood
was spiked with 10-fold serial dilutions of quantified culture stock
of gram-positive bacteria (Streptococcus pyogenes or S. aureus), gram-
negative bacterium (K. pneumoniae), or an RNA virus (enterovirus)
and tested using individual RT-qPCR reactions. Spiked blood
specimens were extracted directly or incubated with TE buffer or
TE buffer containing lytic enzymes at 37uC for 60 min. prior to
extraction. Ct values for spiked blood experiments were compared
using Student’s two-tailed t test.
Individual Real-time PCR Assay Performance
All individual real-time PCR assays were performed on the
Applied Biosystems 7500 Real-Time PCR system (Life Technol-
ogies, Foster City, CA, USA) with the following cycling conditions:
45uC for 10 min, 94uC for 10 min, 45 cycles of 94uC for 30 s and
60uC for 60 s, with data acquisition in the FAM channel during
the 60uC step. Each reaction consisted of 16AgPath-ID One-step
RT-PCR buffer and 16 AgPath-ID One-step RT-PCR enzyme
mix (Applied Biosystems, Foster City, CA, USA) or 16 qScript
XLT One-step RT-qPCR ToughMix, low ROX (Quanta
Biosciences, Gaithersburg, MD, USA), forward and reverse
primers and FAM-labeled hydrolysis probe at the concentrations
listed in Table S1 in File S1, and nuclease-free water to final
volume of 20 mL. Five mL of TNA was used in each reaction.
TAC Assay Performance
TAC assays were performed with slight modification of the
previously reported procedure [7]. Briefly, mastermix for each
TAC consisted of the following: 16AgPath-ID One-step RT-PCR
buffer and enzyme or 16 qScript XLT One-step RT-qPCR
ToughMix. Reactions tested using AgPath enzyme system
consisted of 50 mL 26 buffer, 4 mL 256 enzyme mix, and 46 mL
of TNA. Reactions tested with the qScript ToughMix enzyme
system consisted of 50 mL 26mastermix and 50 mL of TNA. Each
card was centrifuged at 336 6 g for 1 min. twice, to distribute the
fluid in the reaction wells, and sealed to sequester individual
reactions. All TACs were run on the Applied Biosystems ViiA7
Real-Time PCR system (Life Technologies, Foster City, CA, USA)
using the same cycling conditions as used for individual RT-qPCR
reactions. A no template control (NTC) and a positive control
consisting of combined RNA transcripts generated as previously
described [17] were included on each TAC.
Results
Analytical Validation of New Real-time PCR Assays
For each new assay, no amplification was observed in no-
template control (NTC) reactions (n $95) or in reactions
containing nucleic acid from other organisms (n $200, data not
shown). Each assay was also tested for inclusivity within the genus
or species using representative isolates of each subspecies or
serotype as appropriate (Table S2 in File S1). The number of
isolates used for inclusivity testing varied based on availability. The
limit of detection was independently determined for each assay
(Table S2 in File S1).
The target for real-time PCR detection of E. coli also reacts with
the Shigellae. This E. coli/Shigella assay successfully detected all E.
coli types tested, including representative isolates of each virotype
(EHEC, EPEC, ETEC, EAEC, and EIEC), but did not amplify
the closely related species E. albertii, E. hermannii, or E. fergusonii
(data not shown). This assay also detected all four Shigella species
(S. flexneri, S. sonnei, S. dysenteriae, and S. boydii), with the exception of
S. dysenteriae serotype I (data not shown). During development and
validation of this assay, we occasionally observed sporadic
amplification signal in NTC reactions. This was determined to
occur due to residual E. coli DNA present in the enzyme
preparation from the manufacturers, which varied between
production lots. Residual E. coli DNA in extraction reagents may
also contribute to this phenomenon during testing of clinical
specimens. Crossing threshold (Ct) values for this sporadic
amplification were generally found to be .30. For this reason,
we chose to implement a Ct cutoff value of 30 for a more accurate
interpretation of this assay.
Extraction of TNA from Blood and Saline
Direct comparison of Ct values of TNA extracted from blood
spiked with gram-positive bacteria (S. pneumoniae or S. aureus)
revealed that the average Ct value was approximately 5.5 cycles
lower for TNA extracted after incubation with a lytic enzyme
solution compared to identical preparations without this pre-
treatment step (Figure 2A–B). Incubation of spiked blood
specimens with TE buffer alone did not result in lower Ct values,
indicating that the observed improvement in Ct values is a result of
the enzyme treatment instead of simply dilution and heating
(Figure 2). Pre-treatment with lytic enzymes had no significant
impact on Ct values of TNA from blood spiked with the gram-
negative bacterium K. pneumoniae (Figure 2C) or enterovirus (data
not shown).
In addition, the initial lysis step did not significantly impact
target detection in saline spiked with the same serial dilutions (data
not shown). However, comparison of the Ct values for TNA
extracted from blood and saline spiked with the same concentra-
tion of organisms revealed that detection in blood is significantly
impaired relative to saline. The difference in Ct value for detection
of the same number of bacteria in blood compared to saline
ranged from 3.8 cycles at higher concentrations to 11.8 cycles at
lower concentrations (mean difference in Ct value = 6), including a
complete lack of detection of the lowest concentration in blood
(Figure 2D). These data demonstrate the inherent challenge of
detecting pathogens in whole blood specimens.
TAC Preparation: Oligonucleotide Concentration and
Assay Replicates
The impact of oligonucleotide concentration on pathogen
detection was briefly examined using the optimization TAC
configuration (Figure 1). No significant difference in target
amplification was observed at the limit of detection for any of
the four targets examined (data not shown). Additionally, testing of
clinical specimens previously known to be positive for each of these
pathogens did not reveal any oligonucleotide concentration-
dependent difference in target detection (data not shown).
We next aimed to determine the optimal number of replicates
per target needed to maximize pathogen detection, particularly
when the concentration of nucleic acid was near the limit of
detection of the assay. Testing of serial dilutions of nucleic acid
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from M. pneumoniae, S. pneumoniae, S. agalactiae, and PIV2 revealed
excellent concordance between replicates at higher TNA concen-
trations. In contrast, the number of replicate reactions in which
amplification was observed decreased as the concentration
approached the limit of detection for each assay. Testing five
replicates allowed detection of less concentrated nucleic acid
compared to two replicates (data not shown). These results
indicate that testing a higher number of replicates improves
pathogen detection rates when the concentration of organisms is
near the limit of detection.
We also tested primary NP/OP swab and blood specimens in
order to assess the value of testing additional replicates on
pathogen detection. Positive results in clinical specimens were
confirmed by repeat testing in individual RT-qPCR reactions
followed by confirmation of the appropriate size amplicon (data
not shown). The proportion of NP/OP and blood specimens
identified as positive in more than half of assay replicates varied by
target (Figure 3). Overall, this proportion was significantly higher
in NP/OP specimens (Figure 3A) compared to whole blood
(Figure 3B). In other words, while the majority of NP/OP
specimens that were positive were identified as positive in more
than half of assay replicates, amplification of pathogen-specific
targets in whole blood extracts occurred in a much smaller
proportion of total replicates tested. Furthermore, average Ct
values were higher in positive reactions containing TNA extracted
from blood compared to NP/OP swabs (data not shown).
Together these data suggest that a higher number of assay
replicates may identify pathogens which otherwise would be
missed, particularly in whole blood specimens.
Enzyme System Performance with TAC
Finally, we assessed whether different enzyme chemistries
affected target detection in primary clinical specimens. We
hypothesized that newer generations of enzyme mixes may result
in improved detection of pathogen targets, particularly in the
presence of molecules known to have inhibitory effects on real-
time PCR, such as some blood components. We compared the
performance of two enzyme formulations, Ambion AgPath-ID
Figure 2. Effect of lytic enzyme treatment on extraction of nucleic acid from blood specimens. Average Ct value of individual real-time
PCR reactions (n = 4) containing TNA extracted from healthy donor blood spiked with serial dilutions of S. pyogenes (A), S. aureus (B), or K. pneumoniae
(C) without treatment or after incubation with TE buffer alone or TE buffer with lytic enzymes (lysozyme, lysostaphin, and mutanolysin) at 37uC for
30 min. (D) Ct values of serial dilutions of K. pneumoniae spiked into saline (to mimic NP/OP swab) or blood. Error bars display standard deviation.
*p,0.0001 compared to no treatment. # p,0.05 compared to same concentration of organisms in saline.
doi:10.1371/journal.pone.0066183.g002
Optimizing TAC for Identifying Disease Etiology
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e66183
One-step RT-PCR kit (Applied Biosystems) and Quanta qScript
XLT One-step RT-qPCR ToughMix, low ROX (Quanta
Biosciences), at detecting targets in NP/OP specimens (n = 18)
and blood specimens (n = 12) (Figure 4). The median difference in
Ct value for positive results in NP/OP specimens tested with
ToughMix compared to AgPath enzyme varied by target (range
0–4), but overall improved Ct values were observed in reactions
using ToughMix enzyme (Figure 4A). An even more dramatic
improvement in Ct values was observed for blood specimens tested
with ToughMix compared to AgPath; the median difference in Ct
value ranged from 0.46 to 10.5 for various targets (Figure 4B). In
addition, we detected additional positive results (n = 16) for
pathogen-specific targets using the ToughMix enzyme mix that
were not detected when testing the same specimen extract using
AgPath. This phenomenon was not limited to a single pathogen
target, but rather occurred with 12 unique assays (Figure 4). While
a few instances (n = 5) were also observed where the reactions using
AgPath yielded a positive result while the ToughMix reaction was
negative, this occurred only when the Ct value with AgPath was
.33, at the threshold where reproducibility between replicates is
most commonly discordant. Overall, improved pathogen detection
was observed using the ToughMix enzyme system, particularly in
primary blood specimens.
Discussion
The availability of multiple-pathogen detection technologies has
the potential to improve the identification of etiology in a variety
of infectious disease syndromes, ultimately resulting in a more
comprehensive clinical evaluation. The TAC method has recently
been implemented for broad pathogen detection and has proven
to be a valuable tool for identification of infectious etiology
[7,8,11]. Building upon existing data, we sought to improve the
performance of TAC through procedural modifications in order to
enhance pathogen detection for use in a surveillance study of
neonatal infections in South Asia. Experiments were conducted to
optimize performance of this technology, including nucleic acid
extraction, TAC design and production, and use of a newer
generation enzyme mix. We show that considerable improvement
can be achieved by targeted optimization of experimental
parameters (Figure 5). The experiments performed here specifi-
cally address the need for optimization of the entire TAC testing
procedure in order to achieve the highest quality data, a need
which has been recognized by other investigators utilizing TAC
for pathogen detection [10]. These findings may also be applicable
when implementing TAC or other multiple pathogen detection
technologies in the clinical setting or other surveillance studies.
One benefit of TAC technology is the ability to simultaneously
test for numerous pathogens using a relatively small amount of the
primary specimen. With 48 wells available for testing, it is
necessary to balance the number of targets tested and the number
of replicates of each target. Testing of whole blood specimens in
this study revealed that numerous positive results likely would have
been missed if tested using only two replicates of each assay. It is
possible that improved detection for each pathogen is simply due
to increasing the proportion of the specimen which is evaluated by
testing additional replicates, providing more opportunities for the
pathogen-specific nucleic acid to end up in the 1 mL reaction well
containing the appropriate oligonucleotides for amplification.
Indeed, performing a higher number of assays specific for a given
pathogen was previously found to improve detection in blood
collected from murine infection models [10]. While increased
replicate testing improves pathogen detection in whole blood
specimens where pathogen load is commonly low, this approach
necessarily reduces the number of targets for which a single
specimen can be interrogated. Careful consideration was given to
identify the appropriate assays to remove from the blood TAC in
order to improve testing for the most critical pathogens of interest
in neonates on the modified versions of the ANISA study-specific
TACs (Figure 1). Specifically, we increased the number of replicate
wells of pathogen targets for which positive specimens were
identified and selectively removed assays that failed to identify any
positive specimens during pilot phase testing in order to achieve
higher confidence in results from a more focused array of
Figure 3. Concordance between replicates of primary clinical specimens tested on TAC. Concordance between replicate results for NP/OP
(A) and blood (B) specimens tested using TAC. Data shown are total number of specimens identified as positive in at least one replicate reaction
(white bars) and proportion of positive specimens for which greater than 50% of replicates were positive (shaded bars). Number of replicates tested
varied by target and specimen type; all targets were tested in $2 replicates. Total number of specimens tested, NP/OP (n = 124), blood (n = 661).
doi:10.1371/journal.pone.0066183.g003
Optimizing TAC for Identifying Disease Etiology
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e66183
pathogen-specific assays. Careful consideration of the unique
features and logistical challenges associated with implementing
TAC in any setting, whether for clinical use or surveillance, should
occur before customizing TACs.
The results reported here indicate that optimization is required
when utilizing TAC for pathogen detection in whole blood; our
findings may also be applicable to other multiple-pathogen
approaches simultaneously evaluating bacterial and viral agents
and involving multiple specimen types. Overall, substantial
cumulative improvements in Ct values can be realized through
optimization of experimental procedures (Figure 5). For example,
an initial lysis step prior to the automated nucleic acid extraction
procedure improved detection of gram-positive bacterial targets in
whole blood as measured by an average decrease in Ct values of
six cycles (Figure 2), presumably by facilitating destruction of the
peptidoglycan layer and release of cellular contents including
nucleic acid. Treatment with lytic enzymes has previously been
shown to improve bacterial DNA recovery from blood of neonates
[18] and has also been recommended for optimal extraction of
nucleic acid from other specimen types [19–21]. Based on
performance of the selected extraction methods for pathogen
detection in respiratory swab specimens, we chose to perform the
initial lysis treatment on whole blood specimens only for this study.
We selected specimen input and elution volumes in order to
achieve a four-fold concentration of nucleic acid from the original
specimen, which may result in a theoretical improvement of
approximately 1.5 cycles compared to extraction using equal input
and elution volumes (Figure 5). Optimization of nucleic acid
extraction procedures should be performed for all specimen types
since each may provide unique challenges for pathogen detection
using TAC or other multiple pathogen testing strategies.
Extraction via magnetic bead-based methods, such as the platform
used in the current study, has been shown to lessen effects of PCR
inhibitors compared to other extraction methods [22]. This may
be especially important when testing whole blood specimens with
PCR assays. Development and implementation of methods for
specific enrichment of pathogen nucleic acid may further improve
detection in whole blood specimens. Extraction platform (manual
or automated) should also be carefully selected based on site or
study-specific needs; reliability, availability of technical support,
and extent of training required should be considered when
selecting an extraction method for use in a clinical or public health
laboratory or in population-based surveillance studies, particularly
in resource-limited settings.
Use of TAC or other platforms with individual reaction wells
allow the user to customize oligonucleotides for unique assay
variations such as asymmetric primer concentrations, locked
nucleic acid oligonucleotides, inclusion of more than three
oligonucleotides, or other modifications which may be necessary
for optimizing performance of individual assays. This is a
particular advantage for assays intended to detect multiple species,
serotypes, or variants. Although we did not identify any positive
effect of increasing overall oligonucleotide concentration on
performance of several assays on the TAC format, these data
represent only four assays at two different oligonucleotide
concentrations each; therefore, limited conclusions can be drawn
from this evaluation. Carrying out a full assessment of each assay’s
performance at multiple oligonucleotide concentrations was
prohibited by cost and logistical challenges, but this comprehen-
sive analysis may reveal target-specific effects. Optimization of
oligonucleotide concentration in individual real-time PCR reac-
tions prior to implementation on TAC is recommended.
Commercial availability of TACs would obviate the need for this
Figure 4. Effect of enzyme system on detection of pathogen targets in primary clinical specimens. Data shown are difference in Ct value
between reactions using Quanta One-step RT-PCR ToughMix and AgPath-ID One-step RT-PCR kit when testing TNA extracted from NP/OP swabs (A)
or blood (B). Each data point represents the difference in Ct value between the two reactions for an individual clinical specimen. Median difference is
indicated (_) for assays with $2 positive results. *Targets that were only detected using AgPath always occurred when Ct values were .33.
doi:10.1371/journal.pone.0066183.g004
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evaluation when applying this technology for clinical or surveil-
lance purposes.
Through direct comparison of Ct values for positive targets in
primary specimens, we determined that improved detection can be
achieved by selection of an appropriate enzyme formulation.
Newer generation enzyme mixes are more robust and may
demonstrate improved sensitivity compared to historical enzyme
systems; our results show this difference in Ct values may be as
large as 10 cycles (Figure 5). This improvement is particularly
important in blood specimens where the limit of detection is often
significantly higher compared to detection of the same target in
other specimen types, in some cases differing by several orders of
magnitude. This phenomenon may be due, in part, to inhibitory
molecules that can impede pathogen detection. In this case, any
incremental increase in sensitivity is valuable. Additionally,
enzyme formulations available as a 26 mix, including both
systems evaluated in this study, allow for addition of nucleic acid
up to approximately one-half of the total reaction volume, which
may result in a small improvement in Ct value (approximately one
cycle). More highly concentrated enzyme mixes may allow
addition of an even greater proportion of nucleic acid to the
reaction, perhaps further improving pathogen detection. Addi-
tionally, newer enzyme formulations may also exhibit improved
stability and simplified use. For example, the Quanta ToughMix
enzyme system is a true single-tube reaction mix containing all
reagents, including the polymerase and reverse transcriptase
enzymes, whereas most historical RT-PCR mixes, including
AgPath, require separate storage and addition of enzymes to the
mastermix. The stability of the Quanta ToughMix at refrigeration
temperatures is an additional benefit, particularly in laboratories
where reagent storage space in deep freezers may be limited or
unreliable. Minimizing residual E. coli DNA and achieving
consistency in its concentration in production lots may be another
benefit of newer generation enzyme formulations.
While the ability to customize the TAC format is certainly an
attractive feature, this brings with it the complex challenge of
determining the optimal configuration of assays for each
application and producing a customized positive control for all
targets in order to ensure confidence in results. In our experience,
simply combining DNA or RNA from each organism is not a
reliable or feasible option for use as a positive control with the
TAC method. To solve this problem, our laboratory previously
reported design and performance of a plasmid that can be used to
generate RNA transcripts to serve as a positive control for all RT-
qPCR reactions on the TAC [17]. A similar solution may be
applied to other multiple pathogen detection assays. Furthermore,
creating user-friendly databases for storage and analysis of the
large number of data points obtained from these multiple-
Figure 5. Cumulative improvement of pathogen detection with optimization of experimental parameters. Potential improvement in Ct
value (number of cycles) achieved by optimizing each experimental parameter. *Number of cycles gained varies based on organism, target, and
specimen type. #Theoretical improvement calculated based on assumption of 3.3 cycle difference with 10-fold change in nucleic acid concentration.
doi:10.1371/journal.pone.0066183.g005
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pathogen testing modalities is a challenge requiring collaboration
with data management professionals and software programming
specialists.
Here we report further optimization for the implementation of
TAC technology for pathogen detection in clinical specimens.
Despite these technical improvements, other logistical issues
impact the widespread implementation of TAC technology for
routine use in public health laboratories and population-based
surveillance studies. Currently, access is limited due to the lack of a
commercially available complete product; therefore, up-front
production requirements (preparation of oligonucleotides) and
quality control (QC) assessments, which are expensive and labor-
intensive, are the responsibility of the consumer. Commercializa-
tion of TAC will likely be critical for widespread use in laboratories
worldwide. Nonetheless, as the necessary instrumentation and
customized TACs become increasingly accessible at public health
and clinical laboratories, this technology will inevitably increase
the available repertoire of diagnostic tests. To this end, the CDC is
actively pursuing initiatives to transfer this technology to state and
local public health laboratories for use in outbreak settings.
Ultimately, the breadth of testing possible from a small amount of
specimen and the relatively rapid time to results provides distinct
advantages over existing microbiological and molecular diagnostic
methods. Further development and evaluation would be needed in
order to meet regulatory standards set by Clinical Laboratory
Improvement Amendments (CLIA) or the U.S. Food and Drug
Administration (FDA) before this technology may be applied for
patient use in the U.S. Still, expansion of multiple-pathogen
detection systems such as TAC has the potential to improve
patient care on an individual level as well as contribute to the
broader challenge of improving public health overall.
In conclusion, our findings demonstrate multiple techniques
that can be used to optimize detection by TAC; these approaches
may be applicable to other systems that simultaneously detect a
range of pathogen types. Such systems are critically needed for
outbreaks and clinical situations where rapid results are para-
mount, especially if a diverse range of pathogens and specimen
types need to be considered. Implementation of optimized TAC
procedures in the ANISA study will provide our first evaluation of
performance of this technology in a large-scale surveillance study.
The results will greatly improve our understanding of the
pathogens that cause severe illness in neonates in a region of the
world where reducing child mortality is a critical need. More
broadly, utilization of multiple-pathogen detection approaches
such as TAC is likely to increase in the near future and holds
promise to improve the overall clinical microbiological evaluation
of patient specimens for surveillance, outbreak response, and
clinical care.
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